The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review.

Recently approved migraine preventive therapies facilitate rapid control of migraine activity, potentially improving patients' lives and minimizing the societal burden of migraine. This review synthesizes available evidence on rates and timing of early onset of migraine prevention and identifies patient-level outcomes related to early onset prevention. This evidence-based scoping review identified all available clinical trial evidence regarding the early onset of prevention of migraine, under the hypothesis

Informations de copyright

© The Author(s), 2022.

Déclaration de conflit d'intérêts

Declaration of Conflicting Interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: C.G. has been a paid consultant for Alder/Lundbeck, Biohaven, Amgen/Novartis, Theranica, Axsome, Upsher Smith, Spherix Global Insights, and Vorso and has been a past member of speaker bureaus for Amgen/Novartis, Allergan/AbbVie, Biohaven, Lilly, Theranica, and Upsher Smith. He served as an Associate Editor of Headache until 2020 and is a board member of the Headache Cooperative of New England (HCNE). D.C.B. has received grant support from the Food and Drug Administration and the National Headache Foundation and grant support and honoraria from Allergan, Amgen, Lilly, Lundbeck, and Teva. She serves on the editorial board of Current Pain and Headache Reports. M.J.M. has received compensation for consultation from Lundbeck and Theranica. He has participated in speaker bureaus for Lilly and Amgen/Novartis. He has received salary support for serving as principal investigator from Teva, GammaCore, and Allergan/AbbVie. He has received payments for authorship or royalties from Demos Medical, Cambridge University Press, and MedLink. B.T. has received compensation for consulting from Amgen, Novartis, Biohaven, Lilly, Lundbeck, Teva, and Theranica. He has participated in speaker bureaus with Allergan/AbbVie, Amgen, Biohaven, Lilly, Lundbeck, and Teva, and he has received financial compensation for serving as principal investigator with Amgen and Theranica. J.M.P. has received grant support from the National Institutes of Health and compensation for consulting from Alder/Lundbeck, Allergan/AbbVie, Amgen/Novartis, and Biohaven. P.K.D. has received grant support from Amgen/Novartis, Allergan/AbbVie, and Lilly. She serves as Editor in Chief of Migraine Again, Editor at Large of Everyday Health, and Co-Producer/Co-Owner of Migraine World Summit, which is supported by Lundbeck, Impel, Lilly, Allergan/AbbVie, Axon Optics, and Teva. N.L. has no compensation or conflicts to report. All funding or sponsorships are directed to the American Migraine Foundation. A.B. serves as a consultant and/or a promotional speaker for Alder, Allergan, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Novartis, Promius, Supernus, Teva, and Theranica.